Mosquito-Borne Viruses: Fundamental Biology and Therapeutic Intervention
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 8964
Special Issue Editor
Special Issue Information
Dear Colleagues,
An introduction about the Special Issue
Mosquito borne viruses (MBVs) pose serious healthcare challenges. Symptoms of diseases caused by MBVs vary widely in severity, from a mild rash to arthritis, hepatitis, haemorrhagic fever, encephalitis, and congenital defects. The incidence of outbreaks of MBVs has increased steadily over the past few decades. For instance, WHO reports that Dengue virus infections have increased 15-fold in the last two decades in over 100 countries. Nearly 40% of the world population inhabits areas that are considered high-risk for outbreaks of Dengue virus. However, in the last half a decade, outbreaks and epidemics have been caused by newly emerging and re-emerging MBVs, such as the high fatality Eastern Equine Encephalitis Virus, an MBV, whose resurgence was reported in USA in 2019. With medical and scientific focus on the ongoing COVID19 crisis, it is crucial to ensure that research on MBVs is not neglected as they pose a major threat to human health. In this Special Issue on MBVs, we focus on the fundamental biology as well as therapeutic approaches aimed at advancing our understanding of MBV disease mechanism and intervention.
Dr. Syed Saif Hasan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Flavivirus
- Alphavirus
- Infection
- Therapeutics
- Structural Biology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
